298 related articles for article (PubMed ID: 1914843)
1. In vitro studies with Bay V 3522, a new oral cephalosporin.
Thomson KS; Sanders CC; Sanders WE
Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins.
Locher R; Strässle A; Kayser FH
Drugs Exp Clin Res; 1990; 16(10):515-25. PubMed ID: 2100734
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
4. Cefdinir: in vitro activity study and effect of human serum.
García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
Chin NX; Gu JW; Neu HC
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
Doern GV; Tubert TA
Diagn Microbiol Infect Dis; 1990; 13(4):349-52. PubMed ID: 2127558
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
Chin NX; Neu HC
Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of BAY v 3522, a new oral cephalosporin.
Fass RJ
Antimicrob Agents Chemother; 1990 Sep; 34(9):1855-7. PubMed ID: 2126697
[TBL] [Abstract][Full Text] [Related]
10. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
Sultan T; Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
[TBL] [Abstract][Full Text] [Related]
12. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
Neu HC; Saha G; Chin NX
Antimicrob Agents Chemother; 1989 Oct; 33(10):1795-800. PubMed ID: 2589845
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
Johnson DM; Jones RN
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.
Ritchie DJ; Hopefl AW; Milligan TW; Byrne JE; Maddux MS
Clin Ther; 1993; 15(1):107-13. PubMed ID: 8458040
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir.
Payne DJ; Amyes SG
Drugs Exp Clin Res; 1992; 18(6):225-31. PubMed ID: 1478161
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
Briggs BM; Jones RN; Erwin ME; Barrett MS; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(5):425-34. PubMed ID: 1797457
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefcanel versus other oral cephalosporins.
Chin NX; Gu JW; Neu HC
Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):676-82. PubMed ID: 1748125
[TBL] [Abstract][Full Text] [Related]
19. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G
J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.
Neu HC; Chin NX; Labthavikul P
Antimicrob Agents Chemother; 1984 Aug; 26(2):174-80. PubMed ID: 6333207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
